SCHEMBL6560480

SCHEMBL6560480

COc1nc2ccccc2nc1NC(=O)N1CCN(c2ccccc2F)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
POLB P06746 2/20 0.55
HTR1A P08908 1/20 0.54
HTR1D P28221 1/20 0.54
HTR1B P28222 1/20 0.54
HTR2C P28335 1/20 0.54
HTR6 P50406 1/20 0.54
PANK3 Q9H999 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 2/20 0.48
USP2 O75604 1/20 0.48
MAPK1 P28482 1/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
TSHR P16473 2/20 0.47
MEN1 O00255 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927068 0.92 POLB (0.54) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL1138525 0.92 POLB (0.54) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL4918331 0.91 PANK3 (0.58) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL4927114 0.91 TSHR (0.55) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL1138488 0.91 PANK3 (0.58) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL1138341 0.91 TSHR (0.55) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL1138052 0.90 KMT2A (0.52) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL4925496 0.90 KMT2A (0.52) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL6559632 0.89 KMT2A (0.60) KMT2AL3MBTL1POLBHTR1AHTR1D
SCHEMBL6559689 0.88 MAPT (0.57) HTR1AHTR1DHTR1BHTR2CHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1075469-B1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2004-05-26 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS KMT2A 2664/4885L3MBTL1 2717/4885POLB 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.